Research ArticleAccepted Article
Long-term safety of rituximab in primary Sjögren's syndrome: the experience of a single centre
Onorina Berardicurti, Viktoryia Pavlich, Ilenia Di Cola, Piero Ruscitti, Paola Di Benedetto, Luca Navarini, Annalisa Marino, Paola Cipriani and Roberto Giacomelli
The Journal of Rheumatology October 2021, jrheum.210441; DOI: https://doi.org/10.3899/jrheum.210441
Onorina Berardicurti
Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, University of L'Aquila, L'Aquila, Italy; Rheumatology and Immunology Unit, Department of Medicine, University of Rome 'Campus Biomedico', Rome, Italy. Address correspondence to Roberto Giacomelli, MD, PhD. Rheumatology and Immunology Unit, Department of Medicine, University of Rome 'Campus Biomedico', Rome, Italy. e-mail: r.giacomelli@unicampus.it, roberto.giacomelli@univaq.it
Viktoryia Pavlich
Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, University of L'Aquila, L'Aquila, Italy; Rheumatology and Immunology Unit, Department of Medicine, University of Rome 'Campus Biomedico', Rome, Italy. Address correspondence to Roberto Giacomelli, MD, PhD. Rheumatology and Immunology Unit, Department of Medicine, University of Rome 'Campus Biomedico', Rome, Italy. e-mail: r.giacomelli@unicampus.it, roberto.giacomelli@univaq.it
Ilenia Di Cola
Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, University of L'Aquila, L'Aquila, Italy; Rheumatology and Immunology Unit, Department of Medicine, University of Rome 'Campus Biomedico', Rome, Italy. Address correspondence to Roberto Giacomelli, MD, PhD. Rheumatology and Immunology Unit, Department of Medicine, University of Rome 'Campus Biomedico', Rome, Italy. e-mail: r.giacomelli@unicampus.it, roberto.giacomelli@univaq.it
Piero Ruscitti
Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, University of L'Aquila, L'Aquila, Italy; Rheumatology and Immunology Unit, Department of Medicine, University of Rome 'Campus Biomedico', Rome, Italy. Address correspondence to Roberto Giacomelli, MD, PhD. Rheumatology and Immunology Unit, Department of Medicine, University of Rome 'Campus Biomedico', Rome, Italy. e-mail: r.giacomelli@unicampus.it, roberto.giacomelli@univaq.it
Paola Di Benedetto
Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, University of L'Aquila, L'Aquila, Italy; Rheumatology and Immunology Unit, Department of Medicine, University of Rome 'Campus Biomedico', Rome, Italy. Address correspondence to Roberto Giacomelli, MD, PhD. Rheumatology and Immunology Unit, Department of Medicine, University of Rome 'Campus Biomedico', Rome, Italy. e-mail: r.giacomelli@unicampus.it, roberto.giacomelli@univaq.it
Luca Navarini
Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, University of L'Aquila, L'Aquila, Italy; Rheumatology and Immunology Unit, Department of Medicine, University of Rome 'Campus Biomedico', Rome, Italy. Address correspondence to Roberto Giacomelli, MD, PhD. Rheumatology and Immunology Unit, Department of Medicine, University of Rome 'Campus Biomedico', Rome, Italy. e-mail: r.giacomelli@unicampus.it, roberto.giacomelli@univaq.it
Annalisa Marino
Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, University of L'Aquila, L'Aquila, Italy; Rheumatology and Immunology Unit, Department of Medicine, University of Rome 'Campus Biomedico', Rome, Italy. Address correspondence to Roberto Giacomelli, MD, PhD. Rheumatology and Immunology Unit, Department of Medicine, University of Rome 'Campus Biomedico', Rome, Italy. e-mail: r.giacomelli@unicampus.it, roberto.giacomelli@univaq.it
Paola Cipriani
Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, University of L'Aquila, L'Aquila, Italy; Rheumatology and Immunology Unit, Department of Medicine, University of Rome 'Campus Biomedico', Rome, Italy. Address correspondence to Roberto Giacomelli, MD, PhD. Rheumatology and Immunology Unit, Department of Medicine, University of Rome 'Campus Biomedico', Rome, Italy. e-mail: r.giacomelli@unicampus.it, roberto.giacomelli@univaq.it
Roberto Giacomelli
Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, University of L'Aquila, L'Aquila, Italy; Rheumatology and Immunology Unit, Department of Medicine, University of Rome 'Campus Biomedico', Rome, Italy. Address correspondence to Roberto Giacomelli, MD, PhD. Rheumatology and Immunology Unit, Department of Medicine, University of Rome 'Campus Biomedico', Rome, Italy. e-mail: r.giacomelli@unicampus.it, roberto.giacomelli@univaq.it
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Long-term safety of rituximab in primary Sjögren's syndrome: the experience of a single centre
Onorina Berardicurti, Viktoryia Pavlich, Ilenia Di Cola, Piero Ruscitti, Paola Di Benedetto, Luca Navarini, Annalisa Marino, Paola Cipriani, Roberto Giacomelli
The Journal of Rheumatology Oct 2021, jrheum.210441; DOI: 10.3899/jrheum.210441
Accepted manuscript
Long-term safety of rituximab in primary Sjögren's syndrome: the experience of a single centre
Onorina Berardicurti, Viktoryia Pavlich, Ilenia Di Cola, Piero Ruscitti, Paola Di Benedetto, Luca Navarini, Annalisa Marino, Paola Cipriani, Roberto Giacomelli
The Journal of Rheumatology Oct 2021, jrheum.210441; DOI: 10.3899/jrheum.210441